Search Result

Results for "

kappa opioid receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Opioid Receptor (170) 5-HT Receptor (2) Adenylate Cyclase (2) Adrenergic Receptor (1) Aminopeptidase (2) Androgen Receptor (2) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (5) Arrestin (1) Autophagy (3) Caspase (2) CXCR (1) Cytochrome P450 (1) Dopamine Receptor (3) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (5) Enteropeptidase (2) ERK (7) Ferroptosis (3) Histamine Receptor (5) iGluR (2) Interleukin Related (1) Isotope-Labeled Compounds (10) mAChR (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) Mitophagy (3) mTOR (4) Orexin Receptor (OX Receptor) (1) p38 MAPK (5) PINK1/Parkin (3) Potassium Channel (1) Protein Arginine Deiminase (1) Reference Standards (11) Serotonin Transporter (1) Sigma Receptor (1) Sodium Channel (2) TNF Receptor (1) TRP Channel (1) Urotensin Receptor (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (8) Endocrinology (1) Infection (1) Inflammation/Immunology (21) Metabolic Disease (14) Neurological Disease (153)

By Targets:

Opioid Receptor (170)

5-HT Receptor (2)

Adenylate Cyclase (2)

Adrenergic Receptor (1)

Aminopeptidase (2)

Androgen Receptor (2)

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (5)

Arrestin (1)

Autophagy (3)

Caspase (2)

CXCR (1)

Cytochrome P450 (1)

Dopamine Receptor (3)

Drug Derivative (1)

Drug Isomer (1)

Drug Metabolite (1)

Endogenous Metabolite (5)

Enteropeptidase (2)

ERK (7)

Ferroptosis (3)

Histamine Receptor (5)

iGluR (2)

Interleukin Related (1)

Isotope-Labeled Compounds (10)

mAChR (2)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

Mitophagy (3)

mTOR (4)

Orexin Receptor (OX Receptor) (1)

p38 MAPK (5)

PINK1/Parkin (3)

Potassium Channel (1)

Protein Arginine Deiminase (1)

Reference Standards (11)

Serotonin Transporter (1)

Sigma Receptor (1)

Sodium Channel (2)

TNF Receptor (1)

TRP Channel (1)

Urotensin Receptor (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (8)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (21)

Metabolic Disease (14)

Neurological Disease (153)

182

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Opioid Receptor IKK NF-κB

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101718

Aticaprant 5+ Cited Publications CERC-501; LY-2456302	Opioid Receptor	Neurological Disease
Aticaprant (CERC-501) is a potent and centrally-penetrant **kappa opioid** receptor antagonist with a K_i of 0.807 nM.

HY-B0188A

Mianserin hydrochloride 1 Publications Verification Org GB 94	Histamine Receptor Opioid Receptor ERK p38 MAPK	Neurological Disease Metabolic Disease
Mianserin hydrochloride (Org GB 94) is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-76711

Naltrexone	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight .

HY-10487

JDTic dihydrochloride 3 Publications Verification	Opioid Receptor	Neurological Disease
JDTic (dihydrochloride) is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception.

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-13243

Alvimopan 2 Publications Verification ADL 8-2698; LY 246736	Opioid Receptor	Neurological Disease
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

HY-100903

Norbinaltorphimine dihydrochloride 5+ Cited Publications nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride	Opioid Receptor	Neurological Disease
Norbinaltorphimine dihydrochloride (nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride) is a selective, long-acting competitive antagonist of the κ-opioid receptor. Norbinaltorphimine dihydrochloride blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. Norbinaltorphimine dihydrochloride suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. Norbinaltorphimine dihydrochloride is applicable to research related to neurological disorders such as pain .

HY-117040

nor-Binaltorphimine 5+ Cited Publications Norbinaltorphimine; NorBNI	Opioid Receptor	Neurological Disease
nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the κ-opioid receptor. nor-Binaltorphimine blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain .

HY-B0188

Mianserin 1 Publications Verification Mianserine	Histamine Receptor Opioid Receptor ERK p38 MAPK	Neurological Disease
Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-101302

Naltriben mesylate 2 Publications Verification	Opioid Receptor TRP Channel	Inflammation/Immunology
Naltriben mesylate is a potent δ2-opioid receptor antagonist and a TRPM7 activator. Naltriben mesylate shows K_i values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer .

HY-12363

U-69593 1 Publications Verification	Opioid Receptor	Neurological Disease
U-69593 is a potent and selective κ1-opioid receptor agonist . U-69593 attenuates addictive agent-induced behavioral sensitization in the rat . U-69593 reduces anxiety and enhances spontaneous alternation memory in mice . U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum .

HY-P3445A

Anrikefon acetate HSK21542 acetate	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect .

HY-P2159

Dynorphin A (1-8)	Opioid Receptor Endogenous Metabolite	Neurological Disease
Dynorphin A (1-8) is a ligand with preference for the κ-opioid receptor, and its IC₅₀ value against human placental κ-opioid receptor is 330 nM. Dynorphin A (1-8) mediates neuroprotective effects by inhibiting oxidative stress, suppressing apoptosis, and competitively displacing the binding of κ partial agonists. Dynorphin A (1-8) is the dominant opioid peptide in human placental villi and tissue extracts; it undergoes rapid hydrolysis and can enter the central nervous system via intranasal administration. Dynorphin A (1-8) can be used in studies related to ischemic stroke .

HY-100845

Salvinorin A Divinorin A	Opioid Receptor	Cardiovascular Disease
Salvinorin A is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with K_i value of 4.3 nm. Salvinorin A is a non-nitrogenous neoclerodane isolated from Salvia divinorum.

HY-P3445

Anrikefon HSK21542	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effect .

HY-123689

Samidorphan ALKS-33; RDC-0313	Opioid Receptor	Neurological Disease
Samidorphan (ALKS-33) is an orally active *opioid* system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals .

HY-P3609

CR 665 2 Publications Verification JNJ 38488502; FE 200665	Opioid Receptor	Neurological Disease
CR 665 (JNJ 38488502) is a peripherally selective *κ-opioid* agonist. CR 665 can activate the kappa opioid receptor with EC₅₀ value of 10.9 nM. CR 665 can be used for the research of peripheral pain .

HY-P0088

Porcine dynorphin A(1-13) Dynorphin A Porcine Fragment 1-13	Opioid Receptor	Others
Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations.

HY-107749

ML 190	Opioid Receptor	Neurological Disease
ML 190 is a selective *κ opioid* receptor (KOR) antagonist with an IC₅₀ of 120 nM and an EC₅₀** of 129 nM, respectively .

HY-107748

5'-Guanidinonaltrindole hydrochloride 5'-GNTI hydrochloride	Opioid Receptor	Neurological Disease
5'-Guanidinonaltrindole (5'-GNTI) hydrochloride is a highly selective and potent κ-opioid receptor antagonist with a K_i of 0.18 nM for human κ-opioid receptor .

HY-P1337

Dynorphin B (1-13) 1 Publications Verification	Opioid Receptor	Neurological Disease
Dynorphin B (1-13) acts as an agonist on **opioid κ-receptor**.

HY-107747

GR 89696	Opioid Receptor	Inflammation/Immunology
GR 89696 is a highly selective κ2 opioid receptor agonist with potential to prevent pruritus .

HY-76711S

Naltrexone-d4	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-15691

PF-04455242	Opioid Receptor mTOR	Neurological Disease Metabolic Disease
PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .

HY-137279

Naloxone methiodide 1 Publications Verification	Opioid Receptor	Inflammation/Immunology
Naloxone methiodide is a peripherally restricted, nonselective, and competitive opioid receptor antagonist. Naloxone methiodide does not penetrate the blood-brain barrier .

HY-P1594A

Dynorphin A (1-10) TFA	Opioid Receptor iGluR	Neurological Disease
Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) (TFA) also blocks NMDA-activated current with an IC₅₀ of 42.0 μM.

HY-N0050

Allomatrine (+)-Allomatrine	Others	Neurological Disease
Allomatrine ((+)-Allomatrine) is an alkaloid from the bark of Sophora japonica. Allomatrine has antinociceptive properties mediated mainly through the activation ofκ-opioid receptors .

HY-101205

ICI-199441 hydrochloride	Opioid Receptor	Cardiovascular Disease Neurological Disease
ICI-199441 hydrochloride is a potent and selective *κ-opioid* receptor agonist with analgesic effects. ICI 199441 hydrochloride can improve heart resistance to ischemia/reperfusion .

HY-15997B

(±)-U-50488 hydrochloride (±)-Trans-(1R,2R)-U-50488 hydrochloride	Opioid Receptor	Neurological Disease
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrochloride is a selective *κ opioid* receptor (KOR)** agonist .

HY-101079

BRL 52537 hydrochloride	Opioid Receptor	Neurological Disease
BRL 52537 hydrochloride is a highly selective *κ-Opioid* receptor (KOR) agonist with K_i**s of 0.24 nM and 1560 nM for κ and μ subtypes, respectively. BRL 52537 hydrochloride decreases ischemia-evoked NO production as a potential mechanism of neuroprotection. BRL 52537 hydrochloride attenuates early stroke damage .

HY-121800

ML138	Opioid Receptor	Others
ML138, a κ opioid receptor agonist, is a MLPCN probe .

HY-P1337A

Dynorphin B (1-13) TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
Dynorphin B (1-13) TFA acts as an agonist on **opioid κ-receptor**.

HY-107750A

Cyprodime hydrochloride	Opioid Receptor	Neurological Disease
Cyprodime hydrochloride is a highly selective μ-opioid receptor antagonist with K_i values of 5.4 nM, 244.6 nM and 2187 nM for μ-, δ- and κ-opioid receptors, respectively. Cyprodime hydrochloride has anti-depressant-like effect .

HY-101307

BNTX maleate 7-Benzylidenenaltrexone maleate	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) maleate is a *δ1-opioid* receptor antagonist with the K_is of 0.1, 10.8, 13.3, and 58.6 nM for δ1, δ2-, μ-, and κ-opioid receptor, respectively. BNTX maleate shows antinociceptive activity .

HY-76657A

Alvimopan dihydrate 2 Publications Verification ADL 8-2698 dihydrate; LY 246736 dihydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-76711R

Naltrexone (Standard)	Reference Standards Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid *receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids* and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-107743

Naloxone benzoylhydrazone NalBzoH	Opioid Receptor	Neurological Disease
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at **opioid-like NOP receptors**. Naloxone benzoylhydrazone has potently analgesia effect .

HY-10486

JDTic	Opioid Receptor	Neurological Disease
JDTic is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

HY-156614

Icalcaprant	Opioid Receptor	Neurological Disease
Icalcaprant is a kappa-opioid receptor antagonist .

HY-169867

BNTX 7-Benzylidenenaltrexone	Opioid Receptor	Neurological Disease
BNTX (7-Benzylidenenaltrexone) is a highly selective δ1 opioid receptor antagonist. BNTX selectively antagonizes the antinociceptive activity mediated by spinal δ₁ opioid receptors, and does not alter the antinociceptive effects mediated by δ₂, μ or κ opioid receptors at selective doses .

HY-19231

DPI-3290 Org 41793	Opioid Receptor	Neurological Disease
DPI-3290 (Org 41793) is a potent and specific **opioid receptors agonist with K_i** values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively. DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity .

HY-15997C

(±)-U-50488 hydrate hydrochloride (±)-Trans-(1R,2R)-U-50488 hydrate hydrochloride	Opioid Receptor	Neurological Disease
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrate hydrochloride is a selective *κ opioid* receptor (KOR)** agonist .

HY-105235

Enadoline CI-977	Opioid Receptor	Neurological Disease
Enadoline (CI-977) is a highly selective, brain-penetrating, and nonpeptide kappa-opioid receptor (KOR) agonist (K_i=1.25 nM). Antinociceptive effects .

HY-123689S1

Samidorphan-d5 ALKS-33-d₅; RDC-0313-d₅	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active *opioid* system modulator that binds with high affinity to *μ-opioid, κ-opioid, and δ-opioid* receptors. Samidorphan is a *μ-opioid* receptor antagonist and a partial agonist at *k-opioid* and *δ-opioid* receptors. Samidorphan acts primarily as an *opioid* receptor antagonist in vivo .

HY-151811

NAQ	Opioid Receptor	Neurological Disease
NAQ is a potent and selective μ opioid receptor partial agonist, with a K_i of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (K_i=132.50 nM) and the κ receptor (K_i=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence .

HY-145128

GR103545 fumarate	Opioid Receptor	Neurological Disease
GR103545 is a potent and selective agonist of the κ-opioid receptor (κ-OR). ¹¹GR103545 is a radiotracer for imaging κ-OR in vivo ^[1]

HY-P1594

Dynorphin A (1-10)	Opioid Receptor iGluR	Neurological Disease
Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC₅₀ of 42.0 μM.

HY-16765

Axelopran TD-1211	Opioid Receptor	Neurological Disease
Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-106732

AT-076	Opioid Receptor	Neurological Disease
AT-076 is an opioid pan antagonist at nociception, *kappa, mu, and delta opioid* receptors, with K_i values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively .

HY-76657

Alvimopan monohydrate ADL 8-2698 monohydrate; LY 246736 monohydrate	Opioid Receptor	Neurological Disease Cancer
Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan monohydrate can be used for the research of postoperative ileus .

Cat. No.	Product Name	Target	Research Area

HY-17609

Difelikefalin 1 Publications Verification CR-845; FE-202845	Opioid Receptor	Neurological Disease Inflammation/Immunology
Difelikefalin (CR-845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease .

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P0185

Endomorphin 1 3 Publications Verification	Opioid Receptor	Neurological Disease
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (K_i: 1.11 nM), displays reasonable affinities for kappa₃ binding sites, with K_i value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .

HY-P3445A

Anrikefon acetate HSK21542 acetate	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect .

HY-P2159

Dynorphin A (1-8)	Opioid Receptor Endogenous Metabolite	Neurological Disease
Dynorphin A (1-8) is a ligand with preference for the κ-opioid receptor, and its IC₅₀ value against human placental κ-opioid receptor is 330 nM. Dynorphin A (1-8) mediates neuroprotective effects by inhibiting oxidative stress, suppressing apoptosis, and competitively displacing the binding of κ partial agonists. Dynorphin A (1-8) is the dominant opioid peptide in human placental villi and tissue extracts; it undergoes rapid hydrolysis and can enter the central nervous system via intranasal administration. Dynorphin A (1-8) can be used in studies related to ischemic stroke .

HY-P3445

Anrikefon HSK21542	Opioid Receptor	Neurological Disease
Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effect .

HY-P3609

CR 665 2 Publications Verification JNJ 38488502; FE 200665	Opioid Receptor	Neurological Disease
CR 665 (JNJ 38488502) is a peripherally selective *κ-opioid* agonist. CR 665 can activate the kappa opioid receptor with EC₅₀ value of 10.9 nM. CR 665 can be used for the research of peripheral pain .

HY-P0088

Porcine dynorphin A(1-13) Dynorphin A Porcine Fragment 1-13	Opioid Receptor	Others
Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations.

HY-P1337

Dynorphin B (1-13) 1 Publications Verification	Opioid Receptor	Neurological Disease
Dynorphin B (1-13) acts as an agonist on **opioid κ-receptor**.

HY-P0186A

Endomorphin 2 TFA	Opioid Receptor	Neurological Disease
Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa₃ binding sites, with K_i value between 20 and 30 nM .

HY-P1594A

Dynorphin A (1-10) TFA	Opioid Receptor iGluR	Neurological Disease
Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) (TFA) also blocks NMDA-activated current with an IC₅₀ of 42.0 μM.

HY-P1337A

Dynorphin B (1-13) TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
Dynorphin B (1-13) TFA acts as an agonist on **opioid κ-receptor**.

HY-P1299A

UFP-101 TFA	Opioid Receptor	Neurological Disease
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect .

HY-P1594

Dynorphin A (1-10)	Opioid Receptor iGluR	Neurological Disease
Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC₅₀ of 42.0 μM.

HY-P0186

Endomorphin 2	Opioid Receptor	Neurological Disease
Endomorphin 2, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa₃ binding sites, with K_i value between 20 and 30 nM.

HY-P1299

UFP-101	Opioid Receptor	Neurological Disease
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pK_i of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect .

HY-W019787

BAM-12P	Opioid Receptor CXCR	Neurological Disease
BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin. BAM-12P can activate *human κ-opioid* receptor (hKOR) with an EC₅₀ of 101 nM and a pEC₅₀ of 6.99. BAM-12P is a ligand for CXCR7 with an EC₅₀** of 175 nM .

HY-P5907

Helianorphin-19	Opioid Receptor	Neurological Disease
Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a K_i of 21 nM and an EC₅₀ of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain .

HY-P1316A

Ac-RYYRWK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the *nociceptin receptor* (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d** of 0.071 nM, but has no affinity for μ-, κ- or δ-opioid receptors .

HY-P0185A

Endomorphin 1 acetate 3 Publications Verification	Opioid Receptor	Neurological Disease
Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioid receptor (K_i: 1.11 nM), displays reasonable affinities for kappa₃ binding sites, with K_i value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid *receptors. Sialorphin TFA regulates the ERK/mTOR* signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

HY-P10203

*μ/κ/δ opioid* receptor agonist 1**	Opioid Receptor	Inflammation/Immunology
μ/κ/δ opioid receptor agonist 1 is a μ opioid receptor (MOR), κ opioid receptor (KOR), and δ opioid receptor (DOR) agonist. μ/κ/δ opioid receptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .

HY-P10177

Acetalin-3	Opioid Receptor	Neurological Disease
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a μ opioid receptor antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10175

Acetalin-1	Opioid Receptor	Neurological Disease
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a μ opioid receptor antagonist with high affinity for μ and κ3 opioid receptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .

HY-P10006

Leumorphin, human	Opioid Receptor	Neurological Disease
Leumorphin, human is a potent **kappa opioid receptor (κ opioid receptor)** agonist. Leumorphin, human inhibits the contraction of the myenteric plexus-longitudinal muscle preparation of the guinea pig ileum .

HY-P3376

Riminkefon	Opioid Receptor	Neurological Disease
Riminkefon is a **kappa opioid receptor** agonist .

HY-P1333A

Dynorphin A TFA	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P3647

[DPro10] Dynorphin A (1-11), porcine	Opioid Receptor Adenylate Cyclase	Neurological Disease
[DPro10] Dynorphin A (1-11), porcine, a N-Alkylated derivative, is a potent κ-opioid receptor agonist with a K_i value of 0.13 nM. [DPro10] Dynorphin A (1-11), porcine has analgesic property .

HY-P3647A

[DPro10] Dynorphin A (1-11), porcine hydrochloride	Opioid Receptor Adenylate Cyclase	Neurological Disease
[DPro10] Dynorphin A (1-11), porcine hydrochloride, a N-Alkylated derivative, is a potent κ-opioid receptor agonist with a K_i value of 0.13 nM. [DPro10] Dynorphin A (1-11), porcine hydrochloride has analgesic property .

HY-P5892

β-Endorphin (1-27) (human)	Opioid Receptor	Neurological Disease
β-Endorphin (1-27) (human) is an *opioid* antagonist that binds μ-, δ-, and κ-opioid receptors with K_is of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .

HY-P1316

Ac-RYYRWK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the *nociceptin receptor* (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d** of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors .

HY-P3634

[DAla2] Dynorphin A (1-13), amide (porcine)	Opioid Receptor	Neurological Disease
[DAla2] Dynorphin A (1-13), amide (porcine) is a petide. [DAla2] Dynorphin A (1-13), amide (porcine) might have the κ opioid receptor agonist effect. [DAla2] Dynorphin A (1-13), amide (porcine) can be used for the research of nervous system .

HY-P1301

[Arg14,Lys15]Nociceptin	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin is a highly potent and selective *NOP receptor* (ORL1; OP4) agonist, with an EC₅₀** of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P4679

(N-Me-Tyr1,N-Me-Arg7,D-Leu-NHEt8)-Dynorphin A (1-8) E2078	Opioid Receptor	Neurological Disease
(N-Me-Tyr1,N-Me-Arg7,D-Leu-NHEt8)-Dynorphin A (1-8) (E-2078), a stable Dynorphin A (1–8) (HY-P2159) analog, is a kappa opioid receptor (KOR) agonist .

HY-P1301A

[Arg14,Lys15]Nociceptin TFA	Opioid Receptor	Neurological Disease
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective *NOP receptor* (ORL1; OP4) agonist, with an EC₅₀** of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioid receptors, with IC₅₀s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .

HY-P1300

[(pF)Phe4]Nociceptin(1-13)NH2	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective *NOP receptor* (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀** of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P1300A

[(pF)Phe4]Nociceptin(1-13)NH2 TFA	Opioid Receptor	Neurological Disease
[(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective *NOP receptor* (OP4) agonist, with a pK_i of 10.68 and a pEC₅₀** of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold) .

HY-P11642

Sialorphin	ERK Androgen Receptor Opioid Receptor Enteropeptidase mTOR Aminopeptidase	Neurological Disease Inflammation/Immunology Cancer
Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid *receptors. Sialorphin regulates the ERK/mTOR* signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992012

CA1001	Opioid Receptor	Neurological Disease Cancer
CA1001 is a small-molecule ZNF74 inhibitor and a peripherally restricted κ/δ dual **opioid receptor** agonist. CA1001 exhibits potent antitumor activity both in vitro and in vivo. CA1001, in combination with immune checkpoint inhibitors, significantly enhances tumor regression. CA1001 activates peripherally restricted κ/δ dual opioid receptors and exerts analgesic effects under conditions of inflammatory pain, neuropathic pain, and mechanical hyperalgesia. CA1001 can be used in research related to melanoma, mechanical hyperalgesia, neuropathic pain, and inflammatory arthritis pain.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0164

Matrine Maximum Cited Publications 18 Publications Verification Matridin-15-one; Vegard; α-Matrine	Alkaloids Piperidine Alkaloids Classification of Application Fields Leguminosae Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a **kappa opioid receptor and u-receptor** agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-110252

Salvinorin B	Terpenoids Labiatae Encelia stenophylla Greene Diterpenoids Plants Source Classification	Opioid Receptor
Salvinorin B is a selective and brain-penetrant kappa opioid receptor (KOPr) agonist with an EC₅₀ of 248 nM and K_i of 2.95 μM. Salvinorin B activates downstream signaling pathways by binding to KOPr, inhibits pain transmission and reduces inflammatory response. Salvinorin B can be used for the researches of inflammation, immunology and neurological disease, such as neuropathic pain, multiple sclerosis and anxiety .

HY-B0188A

Mianserin hydrochloride 1 Publications Verification Org GB 94	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Disease Research Fields Endocrinology Source Classification	Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-P0185

Endomorphin 1 3 Publications Verification	Natural Products Monophenols Pyrrole Alkaloids Neurological Disease Phenols Endogenous metabolite Disease Research Fields Indole Alkaloids Source Classification	Opioid Receptor
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioid receptor (K_i: 1.11 nM), displays reasonable affinities for kappa₃ binding sites, with K_i value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .

HY-P2159

Dynorphin A (1-8)	Structural Classification Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Opioid Receptor Endogenous Metabolite
Dynorphin A (1-8) is a ligand with preference for the κ-opioid receptor, and its IC₅₀ value against human placental κ-opioid receptor is 330 nM. Dynorphin A (1-8) mediates neuroprotective effects by inhibiting oxidative stress, suppressing apoptosis, and competitively displacing the binding of κ partial agonists. Dynorphin A (1-8) is the dominant opioid peptide in human placental villi and tissue extracts; it undergoes rapid hydrolysis and can enter the central nervous system via intranasal administration. Dynorphin A (1-8) can be used in studies related to ischemic stroke .

HY-100845

Salvinorin A Divinorin A	Terpenoids Labiatae Diterpenoids Plants Vachellia nilotica (L.) P. J. H. Hurter & Mabb. Source Classification	Opioid Receptor
Salvinorin A is a potent, unique and short-acting high efficacy kappa-opioid receptor (KOPr) agonist with K_i value of 4.3 nm. Salvinorin A is a non-nitrogenous neoclerodane isolated from Salvia divinorum.

HY-N0050

Allomatrine (+)-Allomatrine	Alkaloids Piperidine Alkaloids Leguminosae Sophora japonica L. Plants Source Classification	Others
Allomatrine ((+)-Allomatrine) is an alkaloid from the bark of Sophora japonica. Allomatrine has antinociceptive properties mediated mainly through the activation ofκ-opioid receptors .

HY-A0115R

Ramiprilat (Standard) HOE 498 diacid (Standard); Ramipril diacid (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .

HY-B0188AR

Mianserin hydrochloride (Standard) Org GB 94 (Standard)	Alkaloids Structural Classification Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Source Classification	Reference Standards Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) (Standard) is the analytical standard of Mianserin hydrochloride. This product is intended for research and analytical applications. Mianserin hydrochloride is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-N0164R

Matrine (Standard) Matridin-15-one (Standard); Vegard (Standard); α-Matrine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Leguminosae Sophora flavescens Aiton Plants Source Classification	PINK1/Parkin Reference Standards Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Standard) is the analytical standard of Matrine. This product is intended for research and analytical applications. Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N12302A

(E/Z)-Scotanamine D (E/Z)-N1-Dihydrocaffeoyl, N10-caffeoyl spermidine	Structural Classification Alkaloids Other Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Solanaceae Plants Source Classification	Drug Derivative
(E/Z)-Scotanamine D is a hydroxycinnamic acid amide found in the roots of Scopolia tangutica. (E/Z)-Scotanamine D is inactive against μ-, δ-, and κ-opioid receptors .

Cat. No.	Product Name	Chemical Structure

HY-76711S

Naltrexone-d4

Naltrexone-d4 is deuterium labeled Naltrexone (HY-76711). Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

HY-B0188S

Mianserin-d3

Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-17609S1

Difelikefalin-d5 hydrochloride
Difelikefalin-d₅ (CR-845-d₅) hydrochloride is the deuterium labeled Difelikefalin (HY-17609). Difelikefalin (CR-845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-B0188AS

Mianserin-d3 hydrochloride

Mianserin-d₃ hydrochloride is the deuterium labeled Mianserin. Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-17609S

Difelikefalin-d5
Difelikefalin-d₅ (CR-845-d₅) is deuterium labeled Difelikefalin. Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease .

HY-W654256

Matrine-d3

Matrine-d₃ (Matridin-d₃) is a deuterium labeled Matrine (HY-N0164). Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-106605S

Flumezapine-d8 hydrochloride

Flumezapine-d₈ (LY 120363-d₈) hydrochloride is deuterated labeled Flumezapine hydrochloride. Flumezapine hydrochloride is a potent and balanced antagonist of the dopamine D2 receptor and the 5-hydroxytryptamine receptor (5-HT receptor). Flumezapine hydrochloride does not alter the increase in serum cortisol caused by κ-opioid receptor agonists. Flumezapine hydrochloride inhibits the conditioned avoidance response in rats and has a low risk of extrapyramidal side effects. Flumezapine hydrochloride can be used in antipsychotic research.

HY-13243S1

Alvimopan-d7

Alvimopan-d₇ (ADL 8-2698-d₇) is deuterium labeled Alvimopan. Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

kappa opioid receptors

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products